摘要
目的探讨影响中晚期宫颈癌同步放化疗疗效的临床病理因素。方法回顾性分析2000-01-01-2006-12-30广西医科大学肿瘤医院妇瘤科收治的经病理确诊且资料完整的88例接受了首次同步放化疗的ⅡB～Ⅳ期宫颈癌患者的临床资料;同时与同期收治的70例行非同步放化疗的ⅡB～Ⅳ期宫颈癌患者进行对比分析。结果(1)同步放化疗组的累积生存率:1、3、5年的生存率分别为89.77%、63.91%、50.03%,中位生存期56个月;非同步放化疗组的累积生存率:1、3、5年的生存率分别为90.00%、47.36%、29.09%,中位生存期(34个月),两组比较差异有统计学意义(P=0.005)。(2)非同步放化疗患者的复发率(15.71%)高于同步放化疗组(4.55%),差异有统计学意义(P=0.017)。(3)顺铂(DDP)增敏化疗的次数、DDP总剂量/总治疗时间比值、外照射放疗(EBRT)总剂量/总治疗时间(OTT)比值是影响中晚期宫颈癌同步放化疗疗效的因素。(4)多因素分析提示肿瘤的病理类型(P<0.1)、DDP总剂量/总治疗时间比值(P<0.05)、EBRT总剂量/OTT比值(P<0.1)是决定预后的独立因素。结论同步放化疗能改善中晚期宫颈癌患者预后,而肿瘤的病理类型、DDP总剂量/总治疗时间比值和EBRT总剂量/OTT比值是影响其疗效的重要因素。
Objective To investigate the clinical pathology factor in the effects of chemo-radiation therapy for advanced cervical cancer. Methods The 88 patients with ⅡB-Ⅳ stage cervical cancer who received chemo-radiation therapy and 70 patients with ⅡB-Ⅳ stage cervical cancer who received non chemo-radiation therapy were analysed retrospectively, and all of them were from Affiliated Tumor Hospital of Guangxi Medical University as well as confirmed by pathology and completed medical records. Results （ 1 ） The survival rates of ehemo-radiation therapy group： in 1 year, 3-year and 5- year were 89. 77%, 63.91% and 50. 03% , the median survival time being 56 months. That was significantly higher than that without chemo-radiation therapy group （ the survival rates in 1 year, 3-year and 5-year were 90.00% and 47.36%, 29.09% and the median survival time was 34 months） （P = 0. 005）. （2） The relapse rate in patients without chemoradiation therapy was statistically significantly higher than that with chemo-radiation therapy （ P = 0. 017 ）. （ 3 ） In the single-factor analysis of the effects of ehemo-radiation therapy for advanced cervical cancer, there were DDP sensitizing the number of chemotherapy, DDP total dose/ratio of the total treatment time, EBRT total dose/OTTtime ratio on the impact effect of factors. （4） Multi-factor analysis suggested that the pathological type of tumor （ P 〈 0. 1 ）, DDP total dose/ratio of the total treatment time （ P 〈 0. 05 ）, EBRT total dose/OqT time ratio （ P 〈 0. 1 ） were to determine the prognosis of independent factors. Conclusion The ehemo-radiation therapy can improve the prognosis of patients with advanced cervical cancer, and the pathological tumor types, DDP total dose/ratio of the total treatment time and total dose EBRT/OTT time ratio affect the efficacy of important factor.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2009年第3期210-213,共4页
Chinese Journal of Practical Gynecology and Obstetrics
关键词
宫颈癌
同步放化疗
cervical cancer
concurrent chemo-radiation therapy
作者简介
贺红英，现在广西医科大学第四附属医院妇产科工作，广西柳州545005
通讯作者：李力，电子信箱：lili@gxmu．net．cn
